Sonnet Cash from 2010 to 2024

SONN Stock  USD 2.79  0.19  6.38%   
Sonnet Biotherapeutics Cash yearly trend continues to be very stable with very little volatility. Cash is likely to drop to about 497.9 K. Cash is the total amount of money in the form of currency that Sonnet Biotherapeutics Holdings has in its possession. This includes all bills, coins, and funds in bank accounts. View All Fundamentals
 
Cash  
First Reported
2006-06-30
Previous Quarter
3.8 M
Current Value
3.6 M
Quarterly Volatility
35.6 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Sonnet Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sonnet Biotherapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.3 M, Interest Expense of 2.4 M or Selling General Administrative of 2.4 M, as well as many indicators such as Price To Sales Ratio of 1.12, Dividend Yield of 0.0 or PTB Ratio of 5.12. Sonnet financial statements analysis is a perfect complement when working with Sonnet Biotherapeutics Valuation or Volatility modules.
  
Check out the analysis of Sonnet Biotherapeutics Correlation against competitors.

Latest Sonnet Biotherapeutics' Cash Growth Pattern

Below is the plot of the Cash of Sonnet Biotherapeutics Holdings over the last few years. Cash refers to the most liquid asset of Sonnet Biotherapeutics, which is listed under current asset account on Sonnet Biotherapeutics Holdings balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Sonnet Biotherapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Sonnet Biotherapeutics account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. Sonnet Biotherapeutics' Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sonnet Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
Cash10 Years Trend
Pretty Stable
   Cash   
       Timeline  

Sonnet Cash Regression Statistics

Arithmetic Mean3,063,343
Geometric Mean643,547
Coefficient Of Variation230.15
Mean Deviation3,846,038
Median524,111
Standard Deviation7,050,299
Sample Variance49.7T
Range27.6M
R-Value0.26
Mean Square Error49.9T
R-Squared0.07
Significance0.35
Slope410,887
Total Sum of Squares695.9T

Sonnet Cash History

2024497.9 K
20222.3 M
20213.1 M
202027.6 M
20197.3 M
2018524.1 K
201735.7 K

Other Fundumenentals of Sonnet Biotherapeutics

Sonnet Biotherapeutics Cash component correlations

About Sonnet Biotherapeutics Financial Statements

Sonnet Biotherapeutics investors utilize fundamental indicators, such as Cash, to predict how Sonnet Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
When determining whether Sonnet Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonnet Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonnet Biotherapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonnet Biotherapeutics Holdings Stock:
Check out the analysis of Sonnet Biotherapeutics Correlation against competitors.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.96)
Revenue Per Share
0.019
Quarterly Revenue Growth
(0.50)
Return On Assets
(0.97)
Return On Equity
(2.65)
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.